News & Events
Digestive Disease Week (DDW)
Come and visit with the Healix team at Digestive Disease Week (DDW) on May 19-21, 2019, in San Diego! We would love to meet with you to discuss how a Healix-managed infusion program can help you achieve your goals of exceptional patient care while growing your...
American Academy of Neurology (AAN) Annual Meeting
Join Healix at the 2019 American Academy of Neurology (AAN) Annual Meeting on May 4-8, 2019, in Philadelphia, Pennsylvania. Our team of Healix representatives will be available at our booth to discuss how a Healix-managed infusion program can help you to provide...
Healix Selects Citus Health to Digitally Transform Communication Streams and Care Coordination
Healix, the nation’s leader in providing physician office-based infusion services, will implement the Citus Health digital solution suite to streamline multi-office healthcare communications and automate documentation workflows to provide the highest-quality...
Healix Announces Strategic Partnership with WeInfuse
SUGAR LAND, TX (December 6, 2018) – Healix, the nation's leader in providing physician office-based infusion services, announces a strategic partnership with WeInfuse, the first and only end-to-end workflow software application purpose-built for infusion centers....
Healix Announces Strategic Partnership with DoseMe for Precision Dosing
SUGAR LAND, TX (July 20, 2018) – Healix, the nation’s leader in physician office based infusion services, announced a strategic relationship with DoseMe, a precision dosing decision support platform specifically for clinical practice. “We are really pleased to...
TA Associates Announces Investment in Healix
BOSTON and SUGAR LAND, Texas, December 18, 2017 – TA Associates, a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Healix, a provider of outsourced alternate-site infusion therapy management...
Healix Relocates to New State-of-the-Art Pharmacy Facility in Sugar Land, Texas
SUGAR LAND, TX (July 28, 2017) – Healix Infusion Therapy, Inc. is proud to announce the relocation of its pharmacy operation to a new, state-of-the-art facility in Sugar Land, Texas. With more than 28 years of sterile compounding services, the Healix Infusion...
Healix is Now a National Provider of Trogarzo™ (ibalizumab-uiyk)
SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the...
Outpatient Treatment of Osteomyelitis with Telavancin
SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in...
Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20%
SUGAR LAND, TX (March 20, 2017) - Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix receive a collection of clinical and...
Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers
SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was conducted of 105 patients treated...
Antimicrobial Regimen and Safety of Pediatric Outpatient Treatment in a POIC
SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric patients...
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia OPAT in a POIC
SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare Research and Quality, Healthcare Cost, and Utilization...
Low Hospital Admission Rates Following POIC-Based Outpatient Treatment with Intravenous Antibiotics
PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study...
Comparison of Outpatient Antimicrobial Therapy (OPAT) in a POIC vs. Traditional Home Health Care
PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) in a physician office infusion center showed improved quality of care in contrast to a traditional home health care setting. A collaborative, retrospective study reviewed patient data...